GTx Incorporated
| Public | |
| Traded as | NASDAQ: GTXI |
| Industry | Pharmaceuticals |
| Founded | September 24, 1997 |
| Headquarters | Memphis, Tennessee, United States |
| Products | Toremifene, Ostarine, Andarine |
| Website | GTxInc.com |
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.[1] Its major product to date is toremifene, and drugs in development include Ostarine and GTx-758. The company has undertaken partnerships with other biotechnology companies such as Merck[2] in the development of drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes.
References
- ↑ "About GTx". Retrieved May 17, 2011.
- ↑ "GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting". Retrieved May 17, 2011.
This article is issued from Wikipedia - version of the Saturday, February 14, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.